GlassScriptPhysician profile
Gina Burbank
NPI 1255808754
$3,303.61
in general payments reported to CMS, 2019-2025
38 companies · $976 in 2025
The $976 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.68 · 2022: $887 · 2023: $640 · 2024: $774 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,314 · Education: $75.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.37 |
| Education | $75.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $485.64 | 2022-2025 | |
| Pfizer INC. | $355.71 | 2021-2025 | |
| Daiichi Sankyo INC. | $327.03 | 2022-2025 | Enhertu, Injectafer |
| Seagen INC. | $217.70 | 2022-2023 | Adcetris, Tukysa, Padcev |
| Merck Sharp & Dohme LLC | $122.75 | 2023-2025 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $113.31 | 2023-2025 | Enhertu, Lynparza, Tagrisso |
| Amgen INC. | $111.20 | 2022-2023 | Blincyto, Kyprolis, Xgeva |
| Janssen Biotech, INC. | $101.78 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Abbvie INC. | $95.78 | 2023-2025 | |
| Eisai INC. | $91.65 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.22 | 2022-2024 | Iclusig, Ninlaro |
| E.R. Squibb & Sons, L.L.C. | $86.80 | 2022-2025 | Opdivo, Opdualag |
| Stemline Therapeutics INC. | $80.85 | 2024-2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $80.17 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $72.54 | 2022-2025 | Rozlytrek, Alecensa, Gavreto |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $67.99 | 2022 | |
| Coherus Oncology, INC. | $65.68 | 2022-2023 | |
| Incyte Corporation | $65.18 | 2024-2025 | Monjuvi, Jakafi |
| Glaxosmithkline, LLC. | $61.77 | 2022-2025 | Ojjaara |
| Lilly USA, LLC | $60.11 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Sobi, INC | $58.57 | 2022-2024 | |
| Celgene Corporation | $48.98 | 2023 | Pomalyst, Opdualag |
| Gilead Sciences, INC. | $43.23 | 2022-2023 | Trodelvy |
| Array Biopharma INC | $36.82 | 2022-2025 | Tukysa, Mektovi, Braftovi |
| Mirati Therapeutics, INC. | $36.59 | 2023 | Krazati |
| G1 Therapeutics, INC. | $36.12 | 2022-2023 | Cosela |
| Taiho Oncology, INC. | $32.34 | 2025 | |
| Pharmaessentia USA Corporation | $28.40 | 2025 | Besremi |
| Tersera Therapeutics LLC | $28.37 | 2025 | Zoladex |
| Pharmacyclics LLC, An Abbvie Company | $26.76 | 2022 | |
| Karyopharm Therapeutics INC. | $24.16 | 2022 | |
| Beone Medicines USA, INC. | $23.33 | 2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $23.01 | 2025 | |
| Adaptive Biotechnologies Corporation | $22.94 | 2025 | Clonoseq |
| Eusa Pharma (US) LLC | $21.37 | 2022 | |
| Genzyme Corporation | $21.12 | 2022 | |
| Puma Biotechnology, INC. | $19.63 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.01 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Burbank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.